Mutational Signatures (v3.5 - November 2025)
DBS13 · GRCh37 · COSMIC v103
Mutational profile
Proportion of a particular doublet base substitution (DBS) mutation type among all DBS mutation types in the signature is represented by the height of each bar. There are 78 strand-agnostic DBS mutation types.
The reason there are 78 strand-agnostic DBS mutation types is as follows. First, there are 4 x 4 = 16 possible source doublet bases. Of these, AT, TA, CG, and GC are their own reverse complement. We can represent the remaining 12 as 6 possible strand-agnostic doublets (e.g. AC represents both AC and its reverse complement, GT). Thus, there are 4+6=10 source doublet bases. Because they are their own reverse complements, AT, TA, CG, and GC can each be substituted by only 6 doublets . For example, AT can be substituted by 3 doublets starting with C: CA, CC, CG. But AT can be substituted by only 2 doublets starting with G: GA and GC. This is because the mutation from AT>GG is already represented by its reverse complement, AT>CC. Similarly AT can be substituted by only 1 doublet starting with T: TA. This is because AT>TC is represented by its reverse complement, AT>GA, and AT>TG is represented by AT>CA. For the remaining doublets, which are not their own reverse-complements, there are 3 x 3 = 9 possible DBS mutation types. Thus, in total there are 4 x 6 + 6 x 9 = 78 strand-agnostic DBS mutation types (see enumeration in the accompanying Excel document).
Proposed aetiology
Associated with homologous recombination deficiency (HRD).
Comments
Found in Degasperi et al. 2022 as DBS17 and is composed primarily of mutations to TC dinucleotides.
Acceptance criteria
| Background | Identification study | First included in COSMIC | |
|---|---|---|---|
| Degasperi et al. 2022 Science | v3.4 | ||
| Identification | NGS technique | Different variant callers | Multiple sequencing centres |
| WGS | Yes | Yes | |
| Technical validation | Validated in orthogonal techniques | Replicated in additional studies | Extended context enrichment |
| Yes | Yes | - | |
| Proposed aetiology | Mutational process | Support | |
| HR deficiency | Statistical association | ||
| Experimental validation | Experimental study | Species | |
| - | - | ||
Summary of the technical and experimental evidence available in the scientific literature regarding the validation of the mutational signature.
Tissue distribution
Commonly extracted across bladder, breast, CNS, head and neck, hepatopancreatobiliary, kidney, ovary, testis, upper gastrointestinal, uterus and a smaller fraction of lung cancers.
Associated signatures
Associated with homologous recombination deficiency (HRD) signatures SBS3, ID6, CN17, and SV3.